Daiichi Sankyo's Prasugrel Shows Reduction Of Recurrent Cardiovascular Events
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced August 22 that a Phase III study showed patients who took prasugrel for acute coronary syndromes were less likely to have a recurrent event than those who took competing Sanofi-Aventis drug clopidogrel. The study was conducted on patients who had a previous cardiovascular or cerebral event. Recurrent rate for prasugrel was 10.8 compared to clopidogrel's 15.4 percent. Daiichi Sankyo and Eli Lilly are jointly applying for approval. (Click here for more - Japanese language